Hot Investor Mandate: Multi Family Office Seeks to Invest in Promising Life Science Companies with Asia Angle

24 Oct

A multi-family office founded in 2017 has offices in multiple countries throughout Asia. The firm is jointed by 12 families and each has a minimum personal or family asset of 30 million USD. Currently, the firm has total assets under management of 34 million USD. Typical Allocations Size of the firm is around 1.5 million USD. The firm invested in 2 companies in the year 2019 and they do not have a strict limit to the number of new investments.

The firm is open to investing in general Bio-medical industries, including medical devices, healthcare IT and therapeutics. The firm has a preference for reproductive medicine and eye-related topics. Any kind of technic, device or service are welcomed under these 2 topics. Besides the topics above, the firm is currently looking for pre-clinical and phase I opportunities in therapeutic companies as well as medical devices and healthcare IT companies that are in development. Apart from the bio-medical industry, the firm also focuses on investing in E-Vehicle related startups.

The firm is looking for companies with Asia Angle, preferably Asia-based or those plan to do R&D in Asia. The firm is typically a co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan VC Firm Seeks Cross-Border Investment Opportunities with Strong Interests in Therapeutics and Digital Health

24 Oct

A Taiwan-based VC with additional offices in USA has invested primarily in Taiwanese companies, but actively considers those based in the US as well. The firm invests primarily in therapeutics and digital health. The firm looks to be an active investor, and can help those companies looking to expand to the US. The firm invests early, in seed-early stage rounds, and generally makes a first investment of between $500K-1M.

The firm primarily invests in therapeutics and digital health, although will consider investing in medical devices or diagnostics if the company is exceptional. For therapeutics technology, the firm is agnostic to indication and will invest as early as proof of concept stage, although some animal data is preferable. For digital health companies, the firm is fairly flexible with regards to stage of development and will consider most healthcare-related or IoT technologies (e.g. smart hospital applications).

The firm looks for companies with great teams, whether they are experienced entrepreneurs or not. For companies based in Taiwan, the firm prefers to lead investments and take a board seat, playing an active role after investment. For US-based companies, the firm will generally co-invest and may recommend a partner to the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Medical Device Arm of Large Chinese Pharma Seeks to Invest in and Support Commercialization of Early-Stage Life Science Companies

24 Oct

A medical device of a large Chinese pharmaceutical company has 226 affiliated companies with a total of over 8,000 employees, making over 3 billion revenue each year. The firm is interested in early-stage diagnostics, medical device and healthcare IT companies, but will also consider drugs in applicable cases.

The firm is generally interested in medical devices, diagnostics, and Digital healthcare companies with a preference for healthcare platform and CFDA approved companies. The firm will look at different stage companies that are investing in angel to pre-A, and IPO companies and provide investment consulting services to the firm

The firm invests globally but prefers companies with Chinese backgrounds. The firm strongly prefers companies with at least one Mandarin speaker in the management teams. The firm is willing to work with academic researchers or companies that are in very early stages and can provide supports in commercialization using the firm’s already-established internet platforms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: R&D Subsidiary of China Pharma Seeks Various Partnerships with Digital Health Technologies & Early-Stage Therapeutics Across Various Modalities

24 Oct

An R&D subsidiary of a Chinese pharmaceutical focuses on novel therapeutics. In the meantime, the firm is also responsible for sourcing global technology assets for the parent company. The firm is interested in Therapeutics and Healthcare IT opportunities. Fully funded by the parent company, the firm’s allocation size varies for the case to case, no upper limit, and in addition to investment the firm is also interested in co-development, in-licensing, and acquiring.

The firm is especially interested in Antibody therapeutics including new structure antibodies, Gene Therapy, CAR-T Therapy, Targeted Therapy, oncolytic virus therapy, and rare disease. Any combination of AI technology and therapeutics is preferred. For therapeutics, the firm focuses on products in pre-clinical and Phase I stage and will consider orphan indications.

The firm has no specific requirements for company and management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Taiwan, Leading The Way in the Asia Life Science Ecosystem – Spotlight: RESI Taiwan

17 Oct

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Historically, Taiwan has been a technology powerhouse with a ubiquitous presence in microelectronics that reach into the personal devices, homes, offices, and cars of consumers around the world.  Taiwan has established its presence in the life science industry and is a premier player in Asia, and is now making a mark on the global stage.

Taiwan is reaping the benefit of having a clear life science vision and then mastering the execution of that vision by building a world class life science innovation ecosystem.  Taiwan’s stand-out performance in life sciences begins with a well-protected IP and legal environment. Taiwan has also developed comprehensive biomedical clusters and supply chains that lead the way for the Pacific Rim players.  For drug developers, few countries can compete with their healthcare and clinical trial infrastructure. Not to mention, in 1996 they digitized the country’s 23M patient records.  When you add in their world-class NHIA database and the Taiwan Biobank, it all adds up to a superior environment for healthcare development and clinical trials.  To top it off, the government of Taiwan leads the way with holistic support and regulation, making Taiwan the go-to country for life science development.

Over the last two years, I have spent some time delving into the life science landscape of Taiwan. I always talk about the tsunami of technology surfacing around the planet. I have witnessed firsthand how Taiwan is placing itself at the forefront in the life science arena, with cross-border partnerships in the academic and private sectors producing  great results.  Taiwan has a rich entrepreneur base that is creating dynamic technology silos within drugs, devices, diagnostics and digital health. Taiwanese startups and the Taiwanese governmental programs have made Taiwan one of the top healthcare technology hubs on the planet. I have met with Taiwanese entrepreneurs who are developing next generation micro-machine technologies that will impact the way we treat and diagnose patients in a wide range of diseases. I have seen these developers using custom silicon-based medical devices that will monitor patients both inside and outside the body, feeding a new generation of data to a bevy of new AI applications.

There is so much more going on in Taiwan you really need to go there and see for yourself. Best-in-class therapeutics, robotics, medical devices and digital health…it’s all there sitting in Taiwan as we speak. LSN is helping these entrepreneurs get from a regional mindset to a global strategy for partnering and commercialization of all this technology.

Life Science Nation has partnered with Ministry of Science and Technology (MOST) and NARLabs to organize an inaugural RESI Conference in Taipei, Taiwan on November 14th.   Attending RESI Taipei will be a great chance for LSN’s global partners to get plugged into the Taiwan’s rising life science ecosystem and meet emerging startups, both local and drawn from RESI’s global network.

Global Family Office BioForum Joins RESI Asia – Part 2 of the Interview with Chuck Stetson

17 Oct

By Nono Hu, Director of Marketing, LSN

Last week, LSN released the first part of a two-part interview with Chuck Stetson, CEO, Stetson Family Office and Founder of the Global Family Office BioForum (GFOB). Part two interview continues the discussion of family office investment in early stage life science companies. Chuck will be representing GFOB at RESI Shanghai on Nov. 12th and RESI Taipei on Nov. 14th, hosting a Fireside Chat at both events to discuss the strategies GFOB employs to help promote early stage investing by partnering family offices with regional angel groups and incubator programs.

To register for RESI and check out the amazing content click here!

 

McDermott, Will & Emery Presents Expert Cross-Border Legal Content at RESI Asia

17 Oct

By Lucy Parkinson, VP of Investor Research, LSN

Cross-border investment is a growing theme in early stage life science, with investors forming global syndicates and moving new technologies toward market in multiple regions simultaneously to maximize their returns.  However, this creates significant complexities at the legal level, both from an investment perspective and also a regulatory one, not to mention creating concerns about IP protection.  Entrepreneurs are often in need of expert advice on these complexities that arise from acting globally.

RESI Shanghai Agenda

In conjunction with RESI Shanghai, our sponsors McDermott, Will & Emery are holding the 3rd China Life Science And Health Care Outbound Legal Symposium at the Ritz Carlton Pudong on November 12th.  This full day track of content from legal experts, focused on cross-border activities and investment topics, will be open to all RESI Shanghai attendees.  Additionally, McDermott, Will & Emery will present a half-day of expert legal content at RESI Taipei on November 14th.

← Older Entries
Newer Entries →